Neeraj Agarwal, MD
Hematology & Oncology · Salt Lake City, UTNPI 1417078221
Payments from drug & device makers
Across 1,661 payments — averaging $19,499 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$15.6M
- Exelixis Inc.$5.7M
- Merck$3.2M
- Janssen Research & Development, LLC$2.3M
- Gilead$1.7M
- AstraZeneca$1.6M
- plus $2.2M from 22 others
Across 132 payments — averaging $1057.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$134K
- Astellas Pharma Global Development$3K
- Novartis$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 398 | $15,597,792 |
| Exelixis Inc. | 596 | $5,717,118 |
| Merck | 95 | $3,222,118 |
| Janssen Research & Development, LLC | 249 | $2,272,751 |
| Gilead | 65 | $1,706,682 |
| AstraZeneca | 22 | $1,622,360 |
| Eli Lilly | 36 | $1,508,052 |
| EMD Serono, Inc. | 10 | $256,364 |
| Eisai Inc. | 103 | $164,082 |
| Amgen | 2 | $95,754 |
| Genentech, Inc. | 15 | $90,120 |
| Bayer | 3 | $77,946 |
| Immunomedics, Inc. | 2 | $11,725 |
| Janssen Global Services, LLC | 26 | $9,588 |
| Astellas Pharma Global Development | 5 | $7,938 |
| Foundation Medicine, Inc. | 3 | $6,162 |
| E.r. Squibb & Sons, L.L.C. | 8 | $4,997 |
| Advanced Accelerator Applications | 4 | $4,778 |
| Seagen Inc. | 2 | $2,859 |
| Astellas Pharma US Inc | 1 | $2,450 |
| Johnson & Johnson | 2 | $1,607 |
| Astrazeneca UK Limited | 2 | $1,541 |
| Coherus Oncology, Inc. | 1 | $1,000 |
| Telix Pharmaceuticals | 5 | $557 |
| Sun Pharmaceutical Industries Inc. | 2 | $523 |
| Janssen Scientific Affairs, LLC | 2 | $170 |
| Sumitomo Pharma America, Inc. | 1 | $87 |
| Genentech USA, Inc. | 1 | $55 |
How this compares
$32,387,176 in reported general payments places this provider in the 95th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Salt Lake City
- Douglas SborovSalt Lake City$7.8M
- Tsewang TashiSalt Lake City$6.7M
- Benjamin MaughanSalt Lake City$5.6M
- Daanish HodaSalt Lake City$2.9M
- Shiven PatelSalt Lake City$2.9M
- Vaia FlorouSalt Lake City$2.3M
- Theresa WernerSalt Lake City$1.9M
- Heloisa SoaresSalt Lake City$1.7M
- Sunil SharmaSalt Lake City$1.5M
- Brian McCluneSalt Lake City$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.